CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone (Cohort A) or subjects who will receive CART123 in combination with ruxolitinib (Cohort B).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 0 do 29 lat.
- •Pacjenci z ostrą białaczką szpikową (AML), która powróciła po leczeniu lub nie odpowiada na chemioterapię.
- •Pacjenci, u których choroba wróciła po przeszczepie komórek macierzystych.
- •Pacjenci, którzy muszą mieć zidentyfikowanego dawcę komórek macierzystych, gotowego do szybkiego przeszczepu po terapii komórkami CART123, jeśli będzie to wskazane.
- •Wystarczająco dobre funkcjonowanie nerek i wątroby.
Simplified criteria — AI translation
Trial details
- Minimum age
- 0 Years
- Maximum age
- 29 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Children's Hospital of Philadelphia
Philadelphia, United States
Trial contact
Cell Therapy Nurse Navigator
Melissa Varghese
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.